The extrapolated OS for Alectinib and Tislelizumab in 1L EGFR negative and ALK negative advanced nonsq-NSCLC was obtained from the published cost-effectiveness analysis literature. This evidence concerns the gene EGFR and non-small cell lung carcinoma.